| 2025-08-07 | 10-Q | 10.1 | Offer Letter, dated June 2, 2025, by and between Registrant and Gregory K. Chow. |
|---|
| 2025-05-08 | 10-Q | 10.4 | Transition and Separation Agreement, dated as of March 13, 2025, by and between Sutro Biopharma, Inc. and Anne Borgman. |
|---|
| 2025-05-08 | 10-Q | 10.3 | Transition and Separation Agreement, dated as of March 13, 2025, by and between Sutro Biopharma, Inc. and Edward C. Albini. |
|---|
| 2025-05-08 | 10-Q | 10.2 | Offer Letter, dated as of March 13, 2025, by and between Sutro Biopharma, Inc. and Jane Chung. |
|---|
| 2025-05-08 | 10-Q | 10.1 | Transition and Separation Agreement, dated as of March 13, 2025, by and between Sutro Biopharma, Inc. and William J. Newell. |
|---|
| 2024-08-13 | 10-Q | 10.1 | Amended 2018 Employee Stock Purchase Plan |
|---|
| 2024-05-13 | 10-Q | 10.1 | Exclusive License Agreement between the Registrant and Ipsen Pharma SAS. |
|---|
| 2024-03-25 | 10-K | 10.43 | Manufacturing Rights Agreement between the Registrant and Vaxcyte, Inc. |
|---|
| 2024-03-25 | 10-K | 10.34 | Amended and Restated 2021 Equity Inducement Plan and forms of award agreements thereunder. |
|---|
| 2024-03-25 | 10-K | 10.30 | Offer Letter, dated January 18, 2023, by and between the Registrant and Anne E. Borgman. |
|---|
| 2024-03-25 | 10-K | 10.24 | Severance and Change in Control Plan of the Company |
|---|
| 2024-03-25 | 10-K | 10.14 | Offer Letter, dated August 28, 2013, by and between the Registrant and Hans-Peter Gerber. |
|---|
| 2023-11-13 | 10-Q | 10.1 | Third Amendment to the Vaxcyte License Agreement between the Registrant and Vaxcyte, Inc. |
|---|
| 2023-08-10 | 10-Q | 10.2 | Consent and Fifth Amendment to Loan and Security Agreement among Oxford Finance LLC, the Lenders (as defined in the certain Loan and Security Agreement, dated as of February 28, 2020) and the Registrant. |
|---|
| 2023-08-10 | 10-Q | 10.1 | Purchase Agreement, dated June 21, 2023, between the Registrant and an affiliate of Blackstone Life Sciences. |
|---|
| 2023-05-15 | 10-Q | 10.3 | Consent and Fourth Amendment to Loan and Security Agreement among Oxford Finance LLC, the Lenders (as defined in the certain Loan and Security Agreement, dated as of February 28, 2020) and the Registrant. |
|---|
| 2023-05-15 | 10-Q | 10.2 | Consent and Third Amendment to Loan and Security Agreement among Oxford Finance LLC, the Lenders (as defined in the certain Loan and Security Agreement, dated as of February 28, 2020) and the Registrant. |
|---|
| 2023-05-15 | 10-Q | 10.1 | Consent and Second Amendment to the Loan and Security Agreement among Oxford Finance LLC, the Lenders (as defined in the certain Loan and Security Agreement, dated as of February 28, 2020) and the Registrant. |
|---|
| 2023-03-30 | 10-K | 10.35 | Letter Agreement, dated December 19, 2022, by and between the Registrant and Vaxcyte, Inc. |
|---|
| 2022-08-08 | 10-Q | 10.3 | First Amendment to the Loan and Security Agreement among Oxford Finance LLC, Silicon Valley Bank, and the Registrant. |
|---|
| 2022-08-08 | 10-Q | 10.2 | License and Collaboration Agreement, dated June 27, 2022, by and between the Registrant and Astellas Pharma Inc. |
|---|
| 2022-08-08 | 10-Q | 10.1 | First Amendment to the Tasly License Agreement |
|---|
| 2022-02-28 | 10-K | 10.31 | Offer Letter, dated December 11, 2015, by and between the Registrant and Arturo Molina. |
|---|
| 2022-02-28 | 10-K | 10.30 | Offer Letter, dated May 23, 2021, by and between the Registrant and Jane Chung. |
|---|
| 2022-02-28 | 10-K | 10.29 | License Agreement, dated December 24, 2021. by and between the Registrant and Tasly Biopharmaceuticals Co., Ltd. |
|---|
| 2022-02-28 | 10-K | 10.28 | Option Agreement, dated October 9, 2021, by and between the Registrant and BioNova Pharmaceuticals Limited. |
|---|
| 2022-02-28 | 10-K | 10.11 | Offer Letter, dated December 11, 2012, by and between the Registrant and Edward C. Albini. |
|---|
| 2021-11-10 | 10-Q | 10.2 | Second Amendment to the Exclusive Patent License and Research Collaboration Agreement |
|---|
| 2021-08-09 | 10-Q | 10.2 | Third Amendment to Lease 888-894 Industrial Road, San Carlos, CA |
|---|
| 2021-05-07 | 10-Q | 10.1 | Severance and Change in Control Plan |
|---|
| 2021-03-18 | 10-K | 10.24 | Severance and Change in Control Plan of the Company |
|---|
| 2021-03-18 | 10-K | 10.11 | Offer Letter, dated August 8, 2018, by and between the Registrant and Linda Fitzpatrick. |
|---|
| 2020-11-05 | 10-Q | 10.1 | Sublease Agreement, dated September 3, 2020, by and between the Company and Five Prime Therapeutics, Inc. |
|---|
| 2020-03-16 | 10-K | 10.22 | Form of Warrant to Silicon Valley Bank pursuant to the Loan and Security Agreement. |
|---|
| 2020-03-16 | 10-K | 10.21 | Form of Warrant to Oxford Finance LLC pursuant to the Loan and Security Agreement. |
|---|
| 2020-03-16 | 10-K | 10.20 | Loan and Security Agreement, dated February 28, 2020, among Oxford Finance LLC, Silicon Valley Bank, and the Registrant. |
|---|
| 2019-11-08 | 10-Q | 10.2 | Amended Form of Performance Stock Unit Agreement under the 2018 Equity Incentive Plan. |
|---|
| 2019-11-08 | 10-Q | 10.1 | Amended Form of Restricted Stock Unit Agreement under the 2018 Equity Incentive Plan. |
|---|
| 2019-04-01 | 10-K | 10.8 | First Amendment to Loan and Security Agreement dated December 5, 2018 among Oxford Finance LLC, Silicon Valley Bank and the Registrant. |
|---|